Letermovir with an AI-recommendation* in CMV-prophylaxis:
How far can we go from here?

MSD supported Industry Symposium (Hall A)

Saturday, October 26

10:00–11:00

Chair: Matthias Stelljes, Münster
CMV-prophylaxis with Letermovir: Clinical evidence and benefits
Rafael de la Cámara, Madrid
For recipients of an allogeneic stem cell transplantation 
a CMV-prophylaxis with Letermovir should be considered for...
... selected CMV-seropositive patients
Guido Kobbe, Düsseldorf
 
... all CMV-seropositive patients
Martin Bornhäuser, Dresden         
Discussion/Conclusions
Matthias Stelljes, Münster
*according ECIL-7 guidelines

© The International Congress on Controversies in Stem Cell and Cellular Therapies (COSTEM).

Contact:
Tel: +44 20 3289 9552